肺癌筛查后侵入性操作的总费用与自付费用:基于全国商业保险人群的诊疗 episode 估算
基于 Clinformatics 商业保险数据库,回顾性纳入 2015–2017 年接受低剂量胸部 CT 肺癌筛查的 55–79 岁患者 6,268 例,7.4% 在 12 个月内接受至少一次侵入性操作,其中 20.1% 确诊肺癌。将筛查及后续操作视为单个诊疗 episode,平均总费用 740.06 美元,平均自付费用 62.46 美元。
要点
- 肺癌筛查后 12 个月内 7.4% 患者接受侵入性操作,高于临床试验报告率。
- 接受操作者中 20.1% 确诊肺癌,女性及 ≥65 岁者更易接受后续操作。
- 将筛查与后续操作合并为单个 episode,平均自付费用仅 62.46 美元。
核心结论
- 商业保险人群中肺癌筛查后侵入性操作率高于临床试验,但将筛查及下游操作视为单个诊疗 episode 时自付费用较温和。
研究设计与样本
- 回顾性队列研究,使用 Clinformatics Data Mart 数据库,纳入 2015–2017 年 55–79 岁接受低剂量胸部 CT 肺癌筛查患者 6,268 例。
- 以低剂量胸部 CT 筛查及 12 个月内下游侵入性操作合并为单个肺癌筛查 episode 进行费用分析。
- 采用线性与逻辑回归分析操作率及费用的相关因素。
诊断标准与关键数值
- 筛查后 12 个月内 7.4%(462/6,268)患者接受至少一次侵入性操作。
- 侵入性操作构成:穿刺活检 69.0%、细胞学 23.6%、支气管镜 18.6%、手术 23.8%。
- 平均每 episode 总费用 740.06 美元,平均每 episode 自付费用 62.46 美元。
临床应用与阅片要点
- 阅片报告可提示后续侵入性操作概率,尤其女性及 ≥65 岁患者。
- 与患者沟通时可将筛查及可能的下游操作视为整体诊疗 episode 讨论费用。
局限性
- 回顾性研究设计,仅纳入商业保险人群,结果外推受限。
- 未报告操作并发症率及长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Consequences of lung cancer screening (LCS) with low-dose chest CT in clinical settings, including procedures, costs, and complications, are incompletely understood. We evaluated downstream invasive procedures after LCS, total and out-of-pocket (OOP) costs of these procedures, and correlates of procedural rates and costs.
METHODS: Using the Clinformatics Data Mart, we retrospectively included patients between ages 55 and 79 years receiving LCS between 2015 and 2017. The types and frequency of downstream invasive procedures (including needle biopsy, bronchoscopy, surgery, and cytology) were described. Treating the LCS examination and downstream procedures as a single LCS episode, we described the per-episode total costs (insurance reimbursement + OOP costs of LCS and downstream procedures) and OOP costs. Correlates of costs were determined using linear and logistic regression.
RESULTS: A total of 6,268 patients received at least one low-dose chest CT; 462 patients (7.4%) received at least one procedure within 12 months after LCS (needle biopsy 69.0%, cytology 23.6%, bronchoscopy 18.6%, surgery 23.8%). Women and patients ≥65 years were more likely to receive a downstream procedure. Ninety-three patients (20.1%) were diagnosed with lung cancer after LCS. The total cost of managing this population of lung screeners was $5,060,511.04, with an average per-episode total cost of $740.06. The aggregate OOP costs to this population of lung screeners was $427,069.74, with an average per-episode OOP cost of $62.46.
CONCLUSIONS: Rates of invasive procedures after LCS in a commercially insured population exceeded those of clinical trials. Considering LCS and associated downstream procedures as an episode of care results in modest OOP cost.
引用
- Tailor TD, Bell S, Fendrick AM, et al. Total and Out-of-Pocket Costs of Procedures After Lung Cancer Screening in a National Commercially Insured Population: Estimating an Episode of Care. J Am Coll Radiol. 2021. PMID: 34600897. doi:10.1016/j.jacr.2021.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。